

REMARKS
STATUS OF THE CLAIMS:

Claims 1 to 52, 60, and 67 to 75 are cancelled.

Claim 62 was amended.

Claims 53 to 59, 61 to 66, and 76 to 77 are pending.


Claim 62 was amended to substitute the plural “sequences” term with the singular “sequence” term to correctly indicate that only a single sequence is encompassed by this claim in view of the Markush group of Claim 53 from which Claim 62 ultimately depends. Applicants right to equivalents of Claim 62 is reserved. No new matter has been added.

If any small matter should remain outstanding after the Patent Examiner has had an opportunity to review the above Remarks, the Patent Examiner is respectfully requested to telephone the undersigned attorney in order to resolve these matters.

Although it is believed no fee is due, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment associated with the filing of this correspondence to Deposit Account Number 19-3880 in the name of the Bristol-Myers Squibb Company.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
609-252-3575


Stephen C. D'Amico
Agent for Applicants
Reg. No. 46,652

Date: January 10, 2006